Actively Recruiting
OPTImal Treatment of Sinus VENOSUS Defect
Led by Centre Chirurgical Marie Lannelongue · Updated on 2023-08-14
60
Participants Needed
13
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Sinus venosus defect (SVD) accounts for 10% of atrial septal defects and is characterized by an anomalous pulmonary venous return in the superior vena cava associated with a high situated atrial septal defect. Since 2013, transcatheter correction of this congenital heart disease has emerged as a new treatment option. The procedure involves placement of a covered stent in the superior vena cava that tunnels the anomalous pulmonary venous return to the left atrium. Preliminary results are limited but promising. The devices to be used depend on anatomic considerations. XXL stents than 70mm are often required. Today, the availability of CE marked stents is limited. There have been recent reports of successful corrections with the specifically developed Optimus XXL 100mm covered stent (ANDRATEC) with compassionate approval from the Agence Nationale de Sûreté du Médicament in France. Setting up a feasibility study to investigate the use of medical devices in this indication was required. The objective of this project is to study the feasibility, efficacy and safety of the Optimus stent in this newly developed transcatheter procedure, in comparison with the gold-standard surgical method. A French national multicenter comparative cohort study including all eligible patients referred for transcatheter correction of SVD was designed. The feasibility of the transcatheter procedures will be investigated beforehand by virtual digital simulation and simulation on a 3D printed model. The procedures will then be performed in centers of the M3C network for complex congenital heart diseases (CARDIOGEN). The primary endpoint will be a composite of efficacy, defined as complete occlusion of the shunt, and safety, defined as the absence of major events at 6 months. The secondary endpoints will be anatomical, functional and psychosocial (quality of life). It is expected that transcatheter treatment gives comparable results to surgery on the primary endpoint. This could justify the further development of this procedure as an alternative to surgery and facilitate the validation of dedicated equipment.
CONDITIONS
Official Title
OPTImal Treatment of Sinus VENOSUS Defect
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 12 years old
- Have sinus venosus defect (SVD) with right ventricular end-diastolic volume enlargement as defined by guidelines
- Indicated for atrial septal defect correction based on medical-surgical meeting and ESC 2020 criteria
- Adult patients who have received study information and signed consent
- Minor patients with no opposition from both parents for data use
- Agree to be followed for the study duration
- Affiliated with or beneficiary of a social security plan
- Minor patients are eligible only for surgical treatment and included descriptively
You will not qualify if you...
- Under guardianship, curatorship, or judicial protection
- Deprived of liberty
- Pregnant or breastfeeding women
- Currently enrolled in another interventional research study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
CHU Bordeaux
Bordeaux, France, 33404
Not Yet Recruiting
2
Hospices Civils de Lyon
Bron, France, 69500
Not Yet Recruiting
3
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63000
Not Yet Recruiting
4
CHU Grenoble
Grenoble, France, 38700
Actively Recruiting
5
Sébastien HASCOËT
Le Plessis-Robinson, France, 92350
Actively Recruiting
6
CHU Lille
Lille, France, 59000
Actively Recruiting
7
Hôpitaux universitaire de Marseille
Marseille, France, 13385
Not Yet Recruiting
8
CHU Nantes
Nantes, France, 44000
Not Yet Recruiting
9
CHU Necker APHP Paris
Paris, France, 75015
Not Yet Recruiting
10
HEGP Paris
Paris, France, 75015
Not Yet Recruiting
11
CHU Toulouse
Toulouse, France, 31300
Not Yet Recruiting
12
Clinique Pasteur, Toulouse
Toulouse, France, 31300
Not Yet Recruiting
13
CHU Tours
Tours, France, 37000
Not Yet Recruiting
Research Team
S
SEBASTIEN HASCOËT
CONTACT
F
FLORENCE LECERF
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here